Free tool
FAERS Monitor: Givlaari
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 212194 or its brand name (Givlaari, Givosiran Sodium). Reports on generic versions are filed under their own applications.
Reports
1,559
Serious
1,173
75% of reports
Hospitalization
758
Death reported
51
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- porphyria acute495
- hospitalisation182
- intentional dose omission119
- nausea118
- product dose omission issue117
- fatigue103
- therapy interrupted103
- pain92
- malaise74
- abdominal pain73
- vomiting67
- ill-defined disorder64
- seizure64
- inappropriate schedule of product administration51
- unevaluable event49
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2020 | 75 |
| 2021 | 135 |
| 2022 | 224 |
| 2023 | 267 |
| 2024 | 310 |
| 2025 | 290 |
| 2026 | 258 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,600 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| porphyria acuteSignal | 495 | 7111.1 | 6454.6 | 2,300,634 |
| intentional dose omissionSignal | 119 | 56.5 | 47.6 | 6,419 |
| therapy interruptedSignal | 103 | 19.5 | 16.2 | 1,790 |
| hospitalisationSignal | 182 | 16.0 | 14.0 | 2,560 |
| ill-defined disorderSignal | 64 | 14.2 | 11.2 | 775 |
| unevaluable eventSignal | 49 | 8.7 | 6.6 | 329 |
| seizureSignal | 64 | 7.5 | 5.9 | 355 |
| product dose omission issueSignal | 117 | 5.4 | 4.5 | 417 |
| abdominal painSignal | 73 | 4.2 | 3.4 | 179 |
| inappropriate schedule of product administrationSignal | 51 | 3.8 | 2.9 | 104 |
| malaiseSignal | 74 | 2.3 | 1.8 | 53 |
| painSignal | 92 | 2.0 | 1.7 | 48 |
| nauseaSignal | 118 | 2.0 | 1.7 | 61 |
| vomiting | 67 | 1.9 | 1.5 | 29 |
| fatigue | 103 | 1.8 | 1.5 | 36 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.